Updating the Treatment Landscape of SLE for Earlier Introduction of Biologics

Marriott Marquis – Shaw/LeDroit Park Room | Supported By: GSK

---

Program Description

Join this live symposium featuring an interactive discussion of how earlier initiation of biologics in patients with SLE may have the potential to change the disease course and improve clinical outcomes.

Facilitated by Dr. Maria Dall’Era, this symposium offers an engaging and fresh perspective on SLE patient care, highlighting the importance of achieving early disease control and the role of biologics in the treatment paradigm.

Within 5 years of an SLE diagnosis, approximately 30–50% of patients experience organ damage, which can increase the risk of mortality.^1–4 Achieving control of disease activity within 1 year of diagnosis is associated with clinical benefits, including reduced organ damage, flare rates and corticosteroid use.⁵ As such, prompt initiation of effective treatments is a key goal of SLE management.⁶ The disease modification framework can help clinicians optimize treatment decisions to reduce disease activity.⁷

We will explore earlier initiation of biologics, which is supported by the 2023 EULAR recommendations for SLE. We will also examine how earlier treatments may alter the underlying immunological processes of SLE to potentially help achieve earlier disease control and slow organ damage progression. Using interactive patient cases and peer-to-peer dialogue, attendees will learn about the practical application of the disease modification framework and understand the key factors to consider when initiating biologics.

This symposium will provide an inclusive space to share knowledge that clinicians can carry forward and implement to help identify appropriate patients for biologic initiation and improve patient outcomes in their practice.

This program is developed and sponsored by GSK.

This is not an official function/event of the American College of Rheumatology.

Speakers

Maria Dall’Era, MD
UCSF
Lupus Clinic and Rheumatology Clinical Research Center
Director
San Francisco, California

References

1. Urowitz MB, et al. Arthritis Care Res (Hoboken). 2012;64:132–7.
2. Stirnadel-Farrant HA, et al. Rheumatol Ther. 2023;10:1183–97.
3. Chambers SA, et al. Rheumatology 2009;48:673–5.
4. Bruce IN, et al. Ann Rheum Dis. 2015;74:1706–13.
5. Nossent J, et al. Lupus 2010;19:949–56.
6. Fanouriakis A, et al. Ann Rheum Dis. 2024;83:15–29.
7. van Vollenhoven R, et al. Lupus Sci Med. 2022;9:e000634.

PSE-US-3253